<unk> , a<unk> (II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA). On 13 May 2013, Servier released a Direct Healthcare Professional Communication which stated that new restrictions for the use of<unk>  are now in place, as randomised trials have shown an increased risk of myocardial infarction. Servier states that the use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture. The European Pharmacovigilance Risk Assessment Committee (PRAC) recommended restriction in the use of<unk> , based on a routine benefit-risk assessment of the medicine, which included data showing a possible increased risk of heart problems, including heart attacks. On 21 February 2014 the European Medicine Agency recommended that<unk>  remain available with restrictions relative to patients with existing heart disease. In 2017, a large study of over 280,000 British and Spanish patients found no increased risk of venous thromboembolism in users of<unk>  compared to alendronate. Servier ceased manufacturing the drug and in 2019, the drug returned the market in the United Kingdom under the name<unk>  Aristo.
Strontium ranelate
Calcium carbonate
Potassium fluoride
Sodium stibogluconate
Ferrous tartrate
Sodium fluoride
Dimethyl methylphosphonate
Lanthanum carbonate